LAPIX appoints Nimbus CEO Abbas Kazimi to board as TIM 3/4 program advances

The board addition comes with LAPIX testing lead candidate LPX-TI641 in more than 75 patients across Phase 1b rheumatoid arthritis and atopic dermatitis studies.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.